Last 12 months
Inside the activity.
0 purchase rows · 57 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 16 |
| Dec 2025 | 0 | 12 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 8 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 4 |
| Jun 2026 | 0 | 8 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 9 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2025 Filed Jun 4, 2025 21:01 UTC |
McGuire AnnieSVP, General Counsel
|
Tax withholdingCommon Stock | 3,505 | $26.74 | $93,723.70 |
DisclosureSEC source: 0001384101-25-000072 · wk-form4_1749070896.xml · nonDerivative · entry 1 McGuire Annie · CIK 0001914620 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,003 F1 · kind: The reporting person is reporting the withholding of 726, 453, 743 and 1,583 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 1,428, 892, 1,463 and 3,117 Restricted Stock Units granted on February 28, 2022, August 5, 2022, March 6, 2023 and March 6, 2024, respectively, and does not represent a sale by the reporting person. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 21:01 UTC |
Chambers RebeccaChief Financial Officer
|
Tax withholdingCommon Stock | 5,370 | $26.74 | $143,593.80 |
DisclosureSEC source: 0001384101-25-000071 · wk-form4_1749070882.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,529 F1 · kind: The reporting person is reporting the withholding of 1,080, 658, 906, 826 and 1,900 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 2,125, 1,295, 1,784, 1,626 and 3,741 Restricted Stock Units granted on July 19, 2021, March 3, 2022 , August 5, 2022, March 6, 2023 and March 6, 2024, respectively, and does not represent a sale by the reporting person. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 21:01 UTC |
Leite JohnChief Commercial Officer-CLIA
|
Tax withholdingCommon Stock | 2,900 | $26.74 | $77,546.00 |
DisclosureSEC source: 0001384101-25-000070 · wk-form4_1749070867.xml · nonDerivative · entry 1 Leite John · CIK 0001991536 · Chief Commercial Officer-CLIA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,349 F1 · kind: The reporting person is reporting the withholding of 816, 501 and 1,583 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 1,606, 986 and 3,117 Restricted Stock Units, respectively, granted on September 1, 2022, March 6, 2023 and March 6, 2024, respectively, and does not represent a sale by the reporting person. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 21:01 UTC |
Wygant JonathanVP, Chief Accounting Officer
|
Tax withholdingCommon Stock | 1,848 | $26.74 | $49,415.52 |
DisclosureSEC source: 0001384101-25-000069 · wk-form4_1749070851.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,915 F1 · kind: The reporting person is reporting the withholding of 381, 363, 344 and 760 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 750, 713, 677 and 1,496 Restricted Stock Units granted on February 22, 2022, August 5, 2022, March 6, 2023 and March 6, 2024, respectively, and does not represent a sale by the reporting person. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 21:00 UTC |
Febbo Phillip G.Chief Scientific & Med Officer
|
Tax withholdingCommon Stock | 2,955 | $26.74 | $79,016.70 |
DisclosureSEC source: 0001384101-25-000068 · wk-form4_1749070838.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,745 F1 · kind: The reporting person is reporting the withholding of 1,688 and 1,267 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 3,324 and 2,494 Restricted Stock Units, respectively, granted on October 2, 2023 and March 6, 2024, respectively, and does not represent a sale by the reporting person. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 21:00 UTC |
Stapley MarcDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 9,399 | $26.74 | $251,329.26 |
DisclosureSEC source: 0001384101-25-000067 · wk-form4_1749070825.xml · nonDerivative · entry 1 Stapley Marc · CIK 0001539796 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 349,237 F1 · kind: The reporting person is reporting the withholding of 1,486, 1,795, 2,477 and 3,641 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 2,926, 3,534, 4,877 and 7,170 Restricted Stock Units granted on June 1, 2021, March 3, 2022, March 6, 2023 and March 6, 2024, respectively, and does not represent a sale by the reporting person. Read SEC document |
| March 07, 2025 Filed Mar 10, 2025 20:43 UTC |
Leite JohnChief Commercial Officer-CLIA
|
SaleCommon Stock | 5,011 | $31.96 | $160,145.55 |
DisclosureSEC source: 0001384101-25-000042 · wk-form4_1741639425.xml · nonDerivative · entry 3 Leite John · CIK 0001991536 · Chief Commercial Officer-CLIA 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,249 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 6, 2024. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $31.71 to $32.44. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 07, 2025 Filed Mar 10, 2025 20:43 UTC |
Leite JohnChief Commercial Officer-CLIA
|
SaleCommon Stock | 2,400 | $31.04 | $74,484.00 |
DisclosureSEC source: 0001384101-25-000042 · wk-form4_1741639425.xml · nonDerivative · entry 2 Leite John · CIK 0001991536 · Chief Commercial Officer-CLIA 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,260 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 6, 2024. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.63 to $31.61. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:43 UTC |
McGuire AnnieSVP, General Counsel
|
GrantCommon Stock | 30,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-25-000041 · wk-form4_1741639413.xml · nonDerivative · entry 1 McGuire Annie · CIK 0001914620 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,508 F1 · kind: Restricted stock units awarded on March 6, 2025 vest 25% on March 2, 2026 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:44 UTC |
Wygant JonathanVP, Chief Accounting Officer
|
GrantCommon Stock | 13,288 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-25-000045 · wk-form4_1741639458.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,763 F1 · kind: Restricted stock units awarded on March 6, 2025 vest 25% on March 2, 2026 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:44 UTC |
Febbo Phillip G.Chief Scientific & Med Officer
|
GrantCommon Stock | 24,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-25-000044 · wk-form4_1741639446.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,700 F1 · kind: Restricted stock units awarded on March 6, 2025 vest 25% on March 2, 2026 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:44 UTC |
Chambers RebeccaChief Financial Officer
|
GrantCommon Stock | 30,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-25-000043 · wk-form4_1741639435.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,899 F1 · kind: Restricted stock units awarded on March 6, 2025 vest 25% on March 2, 2026 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:43 UTC |
Leite JohnChief Commercial Officer-CLIA
|
GrantCommon Stock | 36,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-25-000042 · wk-form4_1741639425.xml · nonDerivative · entry 1 Leite John · CIK 0001991536 · Chief Commercial Officer-CLIA 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,660 F1 · kind: Restricted stock units awarded on March 6, 2025 vest 25% on March 2, 2026 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:43 UTC |
Stapley MarcDirector · Chief Executive Officer
|
GrantCommon Stock | 90,601 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-25-000040 · wk-form4_1741639402.xml · nonDerivative · entry 1 Stapley Marc · CIK 0001539796 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 358,636 F1 · kind: Restricted stock units awarded on March 6, 2025 vest 25% on March 2, 2026 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:41 UTC |
McGuire AnnieSVP, General Counsel
|
SaleCommon Stock | 1,142 | $33.69 | $38,476.49 |
DisclosureSEC source: 0001384101-25-000030 · wk-form4_1741297299.xml · nonDerivative · entry 1 McGuire Annie · CIK 0001914620 · SVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,308 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 4, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $33.5 to $34.00. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:42 UTC |
Febbo Phillip G.Chief Scientific & Med Officer
|
SaleCommon Stock | 3,570 | $33.95 | $121,205.43 |
DisclosureSEC source: 0001384101-25-000032 · wk-form4_1741297319.xml · nonDerivative · entry 2 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,540 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 4, 2024. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $33.56 to $34.42. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:42 UTC |
Febbo Phillip G.Chief Scientific & Med Officer
|
SaleCommon Stock | 4,467 | $32.86 | $146,807.51 |
DisclosureSEC source: 0001384101-25-000032 · wk-form4_1741297319.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,110 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 4, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $32.50 to $33.33. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:41 UTC |
Stapley MarcDirector · Chief Executive Officer
|
SaleCommon Stock | 1,094 | $34.37 | $37,599.14 |
DisclosureSEC source: 0001384101-25-000031 · wk-form4_1741297309.xml · nonDerivative · entry 3 Stapley Marc · CIK 0001539796 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 268,035 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 13, 2024. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $34.29 to $34.41. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:41 UTC |
Stapley MarcDirector · Chief Executive Officer
|
SaleCommon Stock | 23,414 | $33.91 | $794,008.54 |
DisclosureSEC source: 0001384101-25-000031 · wk-form4_1741297309.xml · nonDerivative · entry 2 Stapley Marc · CIK 0001539796 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 269,129 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 13, 2024. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $33.28 to $34.28. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:41 UTC |
Stapley MarcDirector · Chief Executive Officer
|
SaleCommon Stock | 28,189 | $32.82 | $925,247.55 |
DisclosureSEC source: 0001384101-25-000031 · wk-form4_1741297309.xml · nonDerivative · entry 1 Stapley Marc · CIK 0001539796 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 292,543 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 13, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $32.27 to $33.27. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 02, 2025 Filed Mar 3, 2025 21:29 UTC |
McGuire AnnieSVP, General Counsel
|
Tax withholdingCommon Stock | 8,255 | $34.76 | $286,943.80 |
DisclosureSEC source: 0001384101-25-000021 · wk-form4_1741037387.xml · nonDerivative · entry 3 McGuire Annie · CIK 0001914620 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,450 F4 · kind: The reporting person is reporting the withholding of 726, 453, 743 and 6,333 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 1,429, 892, 1,463 and 12,470 Restricted Stock Units granted on February 28, 2022, August 5, 2022, March 6, 2023 and March 6, 2024, respectively, and does not represent a sale by the reporting person. Read SEC document |
| March 02, 2025 Filed Mar 3, 2025 21:30 UTC |
Leite JohnChief Commercial Officer-CLIA
|
Tax withholdingCommon Stock | 7,650 | $34.76 | $265,914.00 |
DisclosureSEC source: 0001384101-25-000026 · wk-form4_1741037448.xml · nonDerivative · entry 3 Leite John · CIK 0001991536 · Chief Commercial Officer-CLIA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,420 F3 · kind: The reporting person is reporting the withholding of 816, 501 and 6,333 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 1,606, 985 and 12,470 Restricted Stock Units, respectively, granted on September 1, 2022, March 6, 2023 and March 6, 2024, respectively, and does not represent a sale by the reporting person. Read SEC document |
| March 02, 2025 Filed Mar 3, 2025 21:30 UTC |
Stapley MarcDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 20,324 | $34.76 | $706,462.24 |
DisclosureSEC source: 0001384101-25-000025 · wk-form4_1741037436.xml · nonDerivative · entry 3 Stapley Marc · CIK 0001539796 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,732 F4 · kind: The reporting person is reporting the withholding of 1,486, 1,795, 2,478 and 14,565 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 2,925, 3,533, 4,878 and 28,681 Restricted Stock Units granted on June 1, 2021, March 3, 2022, March 6, 2023 and March 6, 2024, respectively, and does not represent a sale by the reporting person. Read SEC document |
| March 02, 2025 Filed Mar 3, 2025 21:30 UTC |
Febbo Phillip G.Chief Scientific & Med Officer
|
Tax withholdingCommon Stock | 6,754 | $34.76 | $234,769.04 |
DisclosureSEC source: 0001384101-25-000024 · wk-form4_1741037425.xml · nonDerivative · entry 3 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,577 F3 · kind: The reporting person is reporting the withholding of 1,688 and 5,066 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 3,323 and 9,976 Restricted Stock Units, respectively, granted on October 2, 2023 and March 6, 2024, respectively, and does not represent a sale by the reporting person. Read SEC document |
| March 02, 2025 Filed Mar 3, 2025 21:30 UTC |
Wygant JonathanVP, Chief Accounting Officer
|
Tax withholdingCommon Stock | 4,301 | $34.76 | $149,502.76 |
DisclosureSEC source: 0001384101-25-000023 · wk-form4_1741037413.xml · nonDerivative · entry 1 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,475 F1 · kind: The reporting person is reporting the withholding of 421, 401, 381 and 3,098 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 750, 714, 678 and 5,985 Restricted Stock Units granted on February 22, 2022, August 5, 2022, March 6, 2023 and March 6, 2024, respectively, and does not represent a sale by the reporting person. F2 · balance_after: Includes 506 shares of common stock purchased pursuant to the Veracyte, Inc. Employee Stock Purchase Plan. Read SEC document |
| March 02, 2025 Filed Mar 3, 2025 21:30 UTC |
Chambers RebeccaChief Financial Officer
|
Tax withholdingCommon Stock | 11,070 | $34.76 | $384,793.20 |
DisclosureSEC source: 0001384101-25-000022 · wk-form4_1741037397.xml · nonDerivative · entry 3 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,699 F3 · kind: The reporting person is reporting the withholding of 1,080, 659, 906, 826 and 7,599 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 2,125, 1,296, 1,783, 1626 and 14,964 Restricted Stock Units granted on July 19, 2021, March 3, 2022 , August 5, 2022, March 6, 2023 and March 6, 2024, respectively, and does not represent a sale by the reporting person. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:29 UTC |
McGuire AnnieSVP, General Counsel
|
Tax withholdingCommon Stock | 7,000 | $33.84 | $236,880.00 |
DisclosureSEC source: 0001384101-25-000021 · wk-form4_1741037387.xml · nonDerivative · entry 2 McGuire Annie · CIK 0001914620 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,705 F3 · kind: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of the PSUs and does not represent a sale. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:29 UTC |
McGuire AnnieSVP, General Counsel
|
GrantCommon Stock | 13,466 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-25-000021 · wk-form4_1741037387.xml · nonDerivative · entry 1 McGuire Annie · CIK 0001914620 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,705 F1 · kind: Represents shares of common stock acquired by the Reporting Person upon vesting of certain performance based restricted stock units ("PSUs") on February 27, 2025, upon the certification by the Board of Directors of the Issuer of the achievement of the performance goals set forth therein. F2 · balance_after: Includes 370 shares of common stock purchased on January 31, 2025 pursuant to the Veracyte, Inc. Employee Stock Purchase Plan. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:30 UTC |
Leite JohnChief Commercial Officer-CLIA
|
SaleCommon Stock | 5,746 | $33.84 | $194,444.64 |
DisclosureSEC source: 0001384101-25-000026 · wk-form4_1741037448.xml · nonDerivative · entry 2 Leite John · CIK 0001991536 · Chief Commercial Officer-CLIA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,070 F2 · kind: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of the PSUs and does not represent a sale. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:30 UTC |
Leite JohnChief Commercial Officer-CLIA
|
GrantCommon Stock | 11,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-25-000026 · wk-form4_1741037448.xml · nonDerivative · entry 1 Leite John · CIK 0001991536 · Chief Commercial Officer-CLIA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,816 F1 · kind: Represents shares of common stock acquired by the Reporting Person upon vesting of certain performance based restricted stock units ("PSUs") on February 27, 2025, upon the certification by the Board of Directors of the Issuer of the achievement of the performance goals set forth therein. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:30 UTC |
Stapley MarcDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 34,273 | $33.84 | $1,159,798.32 |
DisclosureSEC source: 0001384101-25-000025 · wk-form4_1741037436.xml · nonDerivative · entry 2 Stapley Marc · CIK 0001539796 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 341,056 F3 · kind: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of the PSUs and does not represent a sale. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:30 UTC |
Stapley MarcDirector · Chief Executive Officer
|
GrantCommon Stock | 67,277 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-25-000025 · wk-form4_1741037436.xml · nonDerivative · entry 1 Stapley Marc · CIK 0001539796 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,329 F1 · kind: Represents shares of common stock acquired by the Reporting Person upon vesting of certain performance based restricted stock units ("PSUs") on February 27, 2025, upon the certification by the Board of Directors of the Issuer of the achievement of the performance goals set forth therein. F2 · balance_after: Includes 707 shares of common stock purchased on January 31, 2025 pursuant to the Veracyte, Inc. Employee Stock Purchase Plan. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:30 UTC |
Febbo Phillip G.Chief Scientific & Med Officer
|
Tax withholdingCommon Stock | 15,672 | $33.84 | $530,340.48 |
DisclosureSEC source: 0001384101-25-000024 · wk-form4_1741037425.xml · nonDerivative · entry 2 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,331 F2 · kind: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of the PSUs and does not represent a sale. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:30 UTC |
Febbo Phillip G.Chief Scientific & Med Officer
|
GrantCommon Stock | 30,589 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-25-000024 · wk-form4_1741037425.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,003 F1 · kind: Represents shares of common stock acquired by the Reporting Person upon vesting of certain performance based restricted stock units ("PSUs") on February 27, 2025, upon the certification by the Board of Directors of the Issuer of the achievement of the performance goals set forth therein. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:30 UTC |
Chambers RebeccaChief Financial Officer
|
Tax withholdingCommon Stock | 11,911 | $33.84 | $403,068.24 |
DisclosureSEC source: 0001384101-25-000022 · wk-form4_1741037397.xml · nonDerivative · entry 2 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,769 F2 · kind: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of the PSUs and does not represent a sale. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:30 UTC |
Chambers RebeccaChief Financial Officer
|
GrantCommon Stock | 23,170 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-25-000022 · wk-form4_1741037397.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,680 F1 · kind: Represents shares of common stock acquired by the Reporting Person upon vesting of certain performance based restricted stock units ("PSUs") on February 27, 2025, upon the certification by the Board of Directors of the Issuer of the achievement of the performance goals set forth therein. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 21:49 UTC |
Chambers RebeccaChief Financial Officer
|
SaleCommon Stock | 527 | $43.85 | $23,108.95 |
DisclosureSEC source: 0001384101-25-000006 · wk-form4_1738792155.xml · nonDerivative · entry 1 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 113,510 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 13, 2024. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 21:47 UTC |
EPSTEIN ROBERT SDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001384101-25-000004 · wk-form4_1736372816.xml · derivative · entry 2 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 21:47 UTC |
EPSTEIN ROBERT SDirector
|
Exercise / conversionCommon Stock | 20,000 | $8.04 | $160,800.00 |
DisclosureSEC source: 0001384101-25-000004 · wk-form4_1736372816.xml · nonDerivative · entry 1 EPSTEIN ROBERT S · CIK 0001252004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 22:16 UTC |
EASTHAM KARINDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.28 | $0.00 |
DisclosureSEC source: 0001384101-25-000002 · wk-form4_1736201774.xml · derivative · entry 4 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2024. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 22:16 UTC |
EASTHAM KARINDirector
|
SaleCommon Stock | 4,691 | $40.50 | $189,995.82 |
DisclosureSEC source: 0001384101-25-000002 · wk-form4_1736201774.xml · nonDerivative · entry 3 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,497 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2024. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $40.37 to $40.78. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 22:16 UTC |
EASTHAM KARINDirector
|
SaleCommon Stock | 5,309 | $40.12 | $213,009.82 |
DisclosureSEC source: 0001384101-25-000002 · wk-form4_1736201774.xml · nonDerivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,188 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $39.46 to $40.36. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 22:16 UTC |
EASTHAM KARINDirector
|
Exercise / conversionCommon Stock | 10,000 | $5.28 | $52,800.00 |
DisclosureSEC source: 0001384101-25-000002 · wk-form4_1736201774.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2024. Read SEC document |
| December 13, 2024 Filed Dec 17, 2024 21:31 UTC |
Stapley MarcDirector · Chief Executive Officer
|
SaleCommon Stock | 400 | $44.14 | $17,656.52 |
DisclosureSEC source: 0001384101-24-000188 · wk-form4_1734471081.xml · nonDerivative · entry 2 Stapley Marc · CIK 0001539796 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,345 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 13, 2024. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $44.03 to $44.33. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 13, 2024 Filed Dec 17, 2024 21:31 UTC |
Stapley MarcDirector · Chief Executive Officer
|
SaleCommon Stock | 5,190 | $43.37 | $225,080.44 |
DisclosureSEC source: 0001384101-24-000188 · wk-form4_1734471081.xml · nonDerivative · entry 1 Stapley Marc · CIK 0001539796 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,745 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 13, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $42.90 to $43.73. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 21:34 UTC |
McGuire AnnieSVP, General Counsel
|
SaleCommon Stock | 18,699 | $44.02 | $823,178.60 |
DisclosureSEC source: 0001384101-24-000185 · wk-form4_1733520875.xml · nonDerivative · entry 1 McGuire Annie · CIK 0001914620 · SVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,869 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 4, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $43.46 to $44.46. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 21:34 UTC |
Febbo Phillip G.Chief Scientific & Med Officer
|
SaleCommon Stock | 3,934 | $44.09 | $173,447.31 |
DisclosureSEC source: 0001384101-24-000186 · wk-form4_1733520886.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,414 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 4, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $43.60 to $44.46. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 21:59 UTC |
Leite JohnChief Commercial Officer-CLIA
|
SaleCommon Stock | 1,050 | $43.25 | $45,407.88 |
DisclosureSEC source: 0001384101-24-000181 · wk-form4_1733349573.xml · nonDerivative · entry 2 Leite John · CIK 0001991536 · Chief Commercial Officer-CLIA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,810 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 1, 2024. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $42.78 to $43.65. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 21:59 UTC |
Chambers RebeccaChief Financial Officer
|
SaleCommon Stock | 7,000 | $43.23 | $302,621.90 |
DisclosureSEC source: 0001384101-24-000180 · wk-form4_1733349562.xml · nonDerivative · entry 2 Chambers Rebecca · CIK 0001823563 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,037 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 13, 2024. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $42.71 to $43.64. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 21:59 UTC |
Wygant JonathanVP, Chief Accounting Officer
|
SaleCommon Stock | 956 | $43.36 | $41,452.45 |
DisclosureSEC source: 0001384101-24-000178 · wk-form4_1733349540.xml · nonDerivative · entry 2 Wygant Jonathan · CIK 0001584145 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,270 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.